Stockscreener 앱 받기
83.22
2.41%
1.96
시간 외 거래:
83.00
-0.22
-0.26%
전일 마감가:
$81.26
열려 있는:
$81.76
하루 거래량:
527.39K
Relative Volume:
0.49
시가총액:
$2.39B
수익:
$55.23M
순이익/손실:
$-164.08M
주가수익비율:
-12.16
EPS:
-6.8461
순현금흐름:
$-208.68M
1주 성능:
+10.84%
1개월 성능:
+13.61%
6개월 성능:
+46.30%
1년 성능:
+12,950%
1일 변동 폭
$81.39
$83.76
1주일 범위
$74.79
$83.76
52주 변동 폭
$0.57
$83.76
넥타테라퓨틱스 Stock (NKTR) Company Profile
명칭
Nektar Therapeutics
전화
(415) 482-5300
주소
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
83.22 | 2.33B | 55.23M | -164.08M | -208.68M | -6.8461 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
넥타테라퓨틱스 Stock (NKTR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 개시 | Wedbush | Neutral |
| 2026-03-17 | 개시 | TD Cowen | Buy |
| 2026-02-10 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-11-26 | 개시 | Citigroup | Buy |
| 2025-06-24 | 재확인 | BTIG Research | Buy |
| 2025-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2025-04-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-03-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-01-08 | 개시 | B. Riley Securities | Buy |
| 2024-12-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-04 | 개시 | Piper Sandler | Overweight |
| 2024-09-30 | 재개 | BTIG Research | Buy |
| 2024-06-28 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-20 | 재개 | JP Morgan | Underweight |
| 2023-11-09 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-02-24 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2022-08-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-31 | 재개 | Jefferies | Hold |
| 2022-04-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-03-15 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-15 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2022-03-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-08 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-09-10 | 개시 | BofA Securities | Neutral |
| 2021-06-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-02-22 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-09-14 | 개시 | JP Morgan | Neutral |
| 2020-06-10 | 다운그레이드 | CFRA | Hold → Sell |
| 2020-05-12 | 재확인 | H.C. Wainwright | Neutral |
| 2020-04-22 | 개시 | The Benchmark Company | Buy |
| 2020-03-30 | 업그레이드 | Goldman | Sell → Neutral |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-03 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-08 | 다운그레이드 | Goldman | Buy → Sell |
| 2019-08-09 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-08-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-08-09 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-03-15 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-06-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | 재확인 | H.C. Wainwright | Buy |
| 2018-04-20 | 개시 | Seaport Global Securities | Buy |
| 2018-04-13 | 재개 | Piper Jaffray | Overweight |
| 2018-04-06 | 재확인 | Mizuho | Buy |
| 2018-04-02 | 재개 | H.C. Wainwright | Buy |
모두보기
넥타테라퓨틱스 주식(NKTR)의 최신 뉴스
ROSEN, A LEADING NATIONAL FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
DEADLINE ALERT for EOSE, SLNO, NKTR, DRVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive - Seeking Alpha
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - ChartMill
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Nektar Therapeutics, Inc. Investors - GlobeNewswire
Nektar Therapeutics stock hits 52-week high at 78.95 USD By Investing.com - Investing.com Canada
Nektar Therapeutics stock hits 52-week high at 78.95 USD - Investing.com
Nektar Therapeutics stock (US6354171056): Is its immunology pipeline strong enough to unlock new ups - AD HOC NEWS
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, A LEADING AND RANKED FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Certain Restricted Stock Unit of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Stock Options of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Common Stock of Nektar Therapeutics are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Nektar Therapeutics (HAM:ITH0) Stock Price & 30 Year Financial Data - GuruFocus
NKTR Shareholder Alert: Nektar Therapeutics Securities Class Action Lawsuit Investors With ... - Bluefield Daily Telegraph
NKTR Shareholder Alert: Nektar Therapeutics Securities - GlobeNewswire
NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Nektar Therapeutics stock: What investors need to know in immunotherapy's next wave - AD HOC NEWS
Press releases provided by CNW - Techaeris
A Look At Nektar Therapeutics (NKTR) Valuation After Rezpegaldesleukin Trial Progress And Litigation Concerns - Sahm
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Secu - GuruFocus
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Oppo - GuruFocus
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
Lawsuit filed for Investors who lost money with shares of Nektar Therapeutics (NASDAQ: NKTR) - openPR.com
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Nektar Therapeutics to Contact the Firm Today! - ACCESS Newswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein - GlobeNewswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline - TMX Newsfile
Nektar (NKTR) Poised for Potential Upside with Upcoming Data Rel - GuruFocus
Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $123 - 富途牛牛
Nektar Goes Silent: What's Behind The Quiet Period? - RTTNews
Citi Adds Nektar Therapeutics (NKTR) to 30-Day Upside Catalyst Watch List - StreetInsider
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Holzer & Holzer Reminds Investors of Lead Plaintiff Deadlines in Shareholder Lawsuits - National Today
Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar - GlobeNewswire
넥타테라퓨틱스 (NKTR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):